WaveMan
WaveMan · Company
APRE · Aprea Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

APRE Aprea Therapeutics (APRE) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001781983
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
13
13F, latest reported quarter

Aprea Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Aprea Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Gilad Oren
President/CEO
BUY
2026-02-02 SECtraded 2026-01-30
28,100
$25.0K
-23.8%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Apr 3, 2025.
  • +8.0% median (+13.2% mean) 90-day return after 6 previous buys.
  • The trade is 7.5% of the 373,720 shares held after it.
  • 1 other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President/CEO Gilad Oren bought about $25.0K of APRE on Jan 30, 2026; 1 other insider bought within 30 days and 13 funds added in the latest 13F quarter.
Hamill John P.
SrVP/CFO/Prin Fin & Acct Ofcr
BUY
2026-02-02 SECtraded 2026-01-30
5,700
$5.1K
-23.8%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Dec 10, 2025.
  • +15.8% median (+16.8% mean) 90-day return after 4 previous buys.
  • The trade is 17.0% of the 33,433 shares held after it.
  • 1 other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SrVP/CFO/Prin Fin & Acct Ofcr Hamill John P. bought about $5.1K of APRE on Jan 30, 2026; 1 other insider bought within 30 days and 13 funds added in the latest 13F quarter.
Duey Marc
Director
BUY
2025-12-11 SECtraded 2025-12-10
21,459
$25.1K
-45.1%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (2 buys, 1 sale), the last on Oct 18, 2024.
  • +18.5% median (+18.5% mean) 90-day return after 2 previous buys.
  • The trade is 8.4% of the 256,155 shares held after it.
  • 1 other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Duey Marc bought about $25.1K of APRE on Dec 10, 2025, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 13 funds added in the latest 13F quarter.
Hamill John P.
SrVP/CFO/Prin Fin & Acct Ofcr
BUY
2025-12-11 SECtraded 2025-12-10
5,000
$5.8K
-45.1%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Oct 11, 2024.
  • +40.6% median (+25.4% mean) 90-day return after 3 previous buys.
  • The trade is 18.0% of the 27,733 shares held after it.
  • 1 other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SrVP/CFO/Prin Fin & Acct Ofcr Hamill John P. bought about $5.8K of APRE on Dec 10, 2025, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 13 funds added in the latest 13F quarter.
Gilad Oren
President/CEO
BUY
2025-04-04 SECtraded 2025-04-03
2,497
$4.5K
-67.7%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Oct 23, 2024.
  • +12.1% median (+17.0% mean) 90-day return after 5 previous buys.
  • The trade is 0.7% of the 345,620 shares held after it.
  • No other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President/CEO Gilad Oren bought about $4.5K of APRE on Apr 3, 2025; 13 funds added in the latest 13F quarter.
33 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 28 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
13 funds bought in last quarter
below 77% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
7.9% of the float short (float per yahoo 2026-10-27) · 2.2 days to cover · settled 2026-10-15
more than 51% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch APRE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-66.2%12M
-70%-47%-23%+0%2025-102025-122026-022026-042026-062026-082026-10 2025-12-10 · Duey Marc bought $25.1K2026-01-30 · Gilad Oren bought $25.0K2025-12-10 · Hamill John P. bought $5.8K2026-01-30 · Hamill John P. bought $5.1K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns APRE: institutional holders (13F)

13F holdings, latest reported quarter
AIGH Capital Management LLC
1,015,541 sh
$814.8K
Nantahala Capital Management, LLC
411,520 sh
$330.2K
Vestal Point Capital, LP
350,000 sh
$280.8K
SPHERA FUNDS MANAGEMENT LTD.
270,000 sh
$216.6K
RENAISSANCE TECHNOLOGIES LLC
105,800 sh
$84.9K

Congress trades in APRE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

APRE planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

APRE mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$72.2K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$15.7K position · as of 2026-06-30
0.0%
Diversified Equity Alpha Master Portfolio
$232 position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$1.9K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$5.2K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$6.4K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
10 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
1 active
2
Phase 2
0 active
1
Phase 3
0 active
4
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 13 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

APRE financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$12.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-47.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-41.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-49.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-188.6%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$13.2M-$14.3M-$15.5M-$113.4M
Net income-$12.6M-$13.0M-$14.3M-$112.7M
EPS (diluted)-1.93-2.35-3.95-67.99
Operating cash flow-$12.9M-$13.6M-$12.2M-$25.0M
Cash$14.6M$22.8M$21.6M$28.8M
SEC XBRL, fiscal years, as known on 2026-10-28

APRE Stock Sonar score 3/7 axes

Find similar shapesCompare

APRE ranks highest on profitability (53rd percentile) and risk and compliance (46th), and lowest on institutional and government (23rd), among Pharma & Biotech peers.

Profitability
53
Inputs
  • Return on equity-47.4% · 55 pct, sector of 545
  • Return on assets-41.3% · 51 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-49.6% · 51 pct, sector of 576
Institutional and government
23
Inputs
  • Funds adding, latest quarter13 · 23 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
46
Inputs
  • Short interest, % of float+7.9% · 46 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Financial health, Growth, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies